Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Why now
Thesis: Nipocalimab data supports JNJ immunology franchise
Catalyst to watch: Regulatory decisions and additional indications
Main risk: Competitive myasthenia gravis market pressures uptake
Why it matters
Long-term extension data supporting sustained gMG control strengthens the case for nipocalimab's label expansion.
Details
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in anti-AChR+a adolescents Retrospective survey in adults identified fluctuating...
Sources
- prnewswire · 2026-09-29 12:03 UTC